Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Princess Maxima Center for Pediatric Oncology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07175415CT.gov HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Not Yet Recruiting | — | — | — |
NCT07498465CT.gov A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia | — | Withdrawn | — | — | — |
NCT07178912CT.gov Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | — | Not Yet Recruiting | — | — | — |
NCT07387926CT.gov Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) | — | Not Yet Recruiting | — | — | — |
NCT07575412CT.gov SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | — | Not Yet Recruiting | — | — | — |
NCT07454226CT.gov ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL | — | Recruiting | — | — | — |
NCT07227584CT.gov ALL Backbone in AYAs | — | Not Yet Recruiting | — | — | — |
NCT05521087CT.gov A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | — | Withdrawn | — | — | — |
NCT07301138CT.gov BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients | — | Not Yet Recruiting | — | — | — |
NCT05745714CT.gov HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Recruiting | — | — | — |
Show 99 more trialsShow fewer
NCT05751044CT.gov HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Recruiting | — | — | — |
NCT07152041CT.gov Newly-diagnosed Pediatric Ph-positive B-ALL Protocol | — | Recruiting | — | — | — |
NCT06861348CT.gov Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCT | — | Not Yet Recruiting | — | — | — |
NCT06533748CT.gov Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma | — | Recruiting | — | — | — |
NCT05827549CT.gov Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT05761171CT.gov A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | — | Active Not Recruiting | — | — | — |
NCT04845035CT.gov Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | — | Withdrawn | — | — | — |
NCT06175702CT.gov Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL | — | Not Yet Recruiting | — | — | — |
NCT05658640CT.gov HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies | — | Recruiting | — | — | — |
NCT05740449CT.gov HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies | — | Withdrawn | — | — | — |
NCT05959720CT.gov Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | — | Recruiting | — | — | — |
NCT06051409CT.gov A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | — | Recruiting | — | — | — |
NCT05581030CT.gov CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | — | Recruiting | — | — | — |
NCT05292664CT.gov Venetoclax Basket Trial for High Risk Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05476770CT.gov Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | — | Recruiting | — | — | — |
NCT05657652CT.gov CAV Regimen for R/R Ph- B-ALL | — | Recruiting | — | — | — |
NCT05192889CT.gov Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax | — | Active Not Recruiting | — | — | — |
NCT05326516CT.gov A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | — | Completed | — | — | — |
NCT04526795CT.gov Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | — | Terminated | — | — | — |
NCT04752163CT.gov DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT04029688CT.gov A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | — | Terminated | — | — | — |
NCT03860844CT.gov Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT03571321CT.gov Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT03913559CT.gov Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03349281CT.gov Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL | — | Completed | — | — | — |
NCT03519984CT.gov EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | — | Terminated | — | — | — |
NCT03515200CT.gov Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03488225CT.gov Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT03147612CT.gov Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03263572CT.gov Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | — | Recruiting | — | — | — |
NCT03007147CT.gov Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT03286634CT.gov ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016 | — | Active Not Recruiting | — | — | — |
NCT03117751CT.gov Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | — | Active Not Recruiting | — | — | — |
NCT02518750CT.gov Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma | — | Terminated | — | — | — |
NCT02881086CT.gov Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | — | Completed | — | — | — |
NCT02413021CT.gov The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens | — | Unknown | — | — | — |
NCT03564704CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | — | Unknown | — | — | — |
NCT03553238CT.gov Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL | — | Unknown | — | — | — |
NCT02553460CT.gov Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | — | Active Not Recruiting | — | — | — |
NCT02779283CT.gov Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT03318419CT.gov Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT02523976CT.gov Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02535806CT.gov Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults | — | Terminated | — | — | — |
NCT02419755CT.gov Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | — | Terminated | — | — | — |
NCT02303821CT.gov Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT02451774CT.gov Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction | — | Unknown | — | — | — |
NCT02228772CT.gov Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults | — | Completed | — | — | — |
NCT02212561CT.gov Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
NCT02003222CT.gov Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT02043587CT.gov Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma | — | Terminated | — | — | — |
NCT01564784CT.gov A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01621477CT.gov T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | — | Terminated | — | — | — |
NCT01593488CT.gov Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children | — | Unknown | — | — | — |
NCT01540812CT.gov Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS | — | Completed | — | — | — |
NCT01513603CT.gov Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia | — | Unknown | — | — | — |
NCT01500161CT.gov Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | — | Terminated | — | — | — |
NCT01424982CT.gov Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT01324180CT.gov Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT01363128CT.gov Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | — | Completed | — | — | — |
NCT01256398CT.gov Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT01186328CT.gov EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | — | Terminated | — | — | — |
NCT01158885CT.gov Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia | — | Terminated | — | — | — |
NCT01187810CT.gov Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | — | Terminated | — | — | — |
NCT01184885CT.gov A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy | — | Completed | — | — | — |
NCT01004497CT.gov First-line Dasatinib Plus Conventional Chemotherapy in Adults With Newly Diagnosed Ph-Positive ALL | — | Completed | — | — | — |
NCT00968253CT.gov RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00792948CT.gov Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia | — | Active Not Recruiting | — | — | — |
NCT00973752CT.gov Treatment of Older Adults With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00907517CT.gov Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247) | — | Terminated | — | — | — |
NCT00940524CT.gov Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00928200CT.gov Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | — | Terminated | — | — | — |
NCT00991744CT.gov Liposomal Cytarabine for Central Nervous System (CNS)-Treatment in High-risk Acute Lymphoblastic Leukemia (ALL) | — | Suspended | — | — | — |
NCT02894645CT.gov Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study | — | Unknown | — | — | — |
NCT00671034CT.gov Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00720109CT.gov Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00557193CT.gov Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00795756CT.gov Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00549848CT.gov Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00476190CT.gov ALL Adult Consortium Trial: Adult ALL Trial | — | Completed | — | — | — |
NCT00776373CT.gov Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies | — | Terminated | — | — | — |
NCT00390793CT.gov Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | — | Completed | — | — | — |
NCT00440726CT.gov Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT00774332CT.gov A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL | — | Unknown | — | — | — |
NCT00439296CT.gov ABT-751 With Chemotherapy for Relapsed Pediatric ALL | — | Terminated | — | — | — |
NCT00184041CT.gov Intensified Post Remission Therapy Containing PEG-Asparaginase | — | Completed | — | — | — |
NCT00186875CT.gov Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00890656CT.gov Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage | — | Completed | — | — | — |
NCT00853008CT.gov Treatment of High Risk Adult Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00671658CT.gov Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00131053CT.gov Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL) | — | Unknown | — | — | — |
NCT00130195CT.gov Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) | — | Completed | — | — | — |
NCT00136435CT.gov A Study in Adults With Untreated Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00176462CT.gov CINJALL: Treatment for Children With Acute Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00165178CT.gov Treatment of Acute Lymphoblastic Leukemia in Children | — | Completed | — | — | — |
NCT00137111CT.gov Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00368355CT.gov T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts | — | Completed | — | — | — |
NCT00526305CT.gov LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive | — | Completed | — | — | — |
NCT00187005CT.gov Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | — | Terminated | — | — | — |
NCT00187083CT.gov A Study of Children With Refractory or Relapsed ALL | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytarabine (this asset) | Princess Maxima Center for Pediatric Oncology | Approved | BB · 70 |
| Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive | Fred Hutchinson Cancer Center | P2/3 | BBB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BBB |
| Equine Atg | Instituto Nacional de Cancer, Brazil | P3 | BBB |
| Pegaspargase | Dana-Farber Cancer Institute | P4 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P4 | BB |
| Methotrexate | Princess Maxima Center for Pediatric Oncology | P4 | BB |
| Vincristine Sulfate | Children's Oncology Group | P3 | BB |
+42 more in the Acute Lymphoblastic Leukemia cohort
Other indications for Cytarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Acute Myeloblastic Leukemia With Maturation | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Peripheral Blood Stem Cells, Allogeneic, Cd34 PositiveFred Hutchinson Cancer CenterBBB
- Gm-CsfXinhua Hospital, Shanghai Jiao Tong University School of MedicineBBB
- Thioguanine AnhydrousSt. Jude Children's Research HospitalBBB
- Equine AtgInstituto Nacional de Cancer, BrazilBBB
- PegaspargaseDana-Farber Cancer InstituteBB
Citation
Floatz Terminal. Cytarabine in Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cytarabine-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →